News

Drug helps patients with relapsed myeloma

BMJ 2003; 327 doi: 10.1136/bmj.327.7405.7-a (Published 3 July 2003)
Cite this as: BMJ 2003;327:7.2

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Janice Hopkins Tanne
  1. New York

    Bortezomib, the first of a new class of drugs called proteasome inhibitors, produced a 35% response rate in patients with relapsed, refractory multiple myeloma, an unusually high rate in these patients, for whom there is no other treatment.

    A phase II study published in the New England Journal of Medicine (2003;348: 2609-17 led the US Food and Drug Administration to grant accelerated approval to Millennium Pharmaceuticals to provide the drug to patients whose disease …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular